Business
High Tide to Become Major Player in German Medical Cannabis Market Through Acquisition of Majority Stake in Remexian Pharma GmbH
High Tide to Become Major Player in German Medical Cannabis Market Through Acquisition of Majorit...
About this update from High Tide, Inc.
[{"type":"text","content":"\n\n\n\n High Tide to Become Major Player in German Medical Cannabis Market Through Acquisition of Majority Stake in Remexian Pharma GmbH\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnml40{\nMARGIN-LEFT:3.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Remexian Generated €65 Million in Revenue in the Last 12 Months\n \n\n\n\n\n\n Remexian Sold 7 Tonnes of Cannabis Flower in Q2 2025, Representing 16% of the 43 Tonnes Imported into\n \n Germany\n \n in the Quarter\n \n 1\n \n\n\n\n\n\n\n CALGARY, AB\n \n\n ,\n \n\n Aug. 14, 2025\n \n\n /CNW/ - High Tide Inc. (\"\n \n High Tide\n \n \" or the\n \n \"Company\n \n \") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it is entering the fast growing German medical cannabis market by signing a definitive agreement (the \"\n \n Acquisition Agreement\n \n \") pursuant to which the Company will acquire 51% of Remexian Pharma GmbH (\"\n \n Remexian\n \n \"), for a preliminary estimated purchase price of €27.2 million, subject to certain adjustments on closing (the \"\n \n Transaction\n \n \"), and will have an option to acquire the remaining interest in Remexian.\n \n\n Founded in 2018 and headquartered just outside of\n \n Berlin, Germany\n \n , Remexian is a leading and established pharmaceutical company built for the purpose of importation and wholesale of medical cannabis, and has a fully certified EU GDP warehouse. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe, currently licensed to import into\n \n Germany\n \n from 19 countries, including\n \n Canada\n \n which represents approximately 33% of their ...